Switch theme
Sign up to access all valuation multiples
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
1994
20.1K+
LTM Revenue $4.0B
LTM EBITDA $963M
$10.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Charles River has a last 12-month revenue (LTM) of $4.0B and a last 12-month EBITDA of $963M.
In the most recent fiscal year, Charles River achieved revenue of $4.0B and an EBITDA of $581M.
Charles River expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Charles River valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $963M | XXX | $581M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $779M | XXX | $442M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $507M | XXX | $10.3M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Charles River's stock price is $155.
Charles River has current market cap of $7.6B, and EV of $10.4B.
See Charles River trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.4B | $7.6B | XXX | XXX | XXX | XXX | $9.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Charles River has market cap of $7.6B and EV of $10.4B.
Charles River's trades at 2.6x EV/Revenue multiple, and 17.8x EV/EBITDA.
Equity research analysts estimate Charles River's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Charles River has a P/E ratio of 15.0x.
See valuation multiples for Charles River and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.6B | XXX | $7.6B | XXX | XXX | XXX |
| EV (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 23.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.0x | XXX | 739.0x | XXX | XXX | XXX |
| EV/FCF | 21.5x | XXX | 20.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCharles River's last 12 month revenue growth is -1%
Charles River's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $44K for the same period.
Charles River's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Charles River's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Charles River and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Charles River acquired XXX companies to date.
Last acquisition by Charles River was XXXXXXXX, XXXXX XXXXX XXXXXX . Charles River acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Charles River founded? | Charles River was founded in 1994. |
| Where is Charles River headquartered? | Charles River is headquartered in United States of America. |
| How many employees does Charles River have? | As of today, Charles River has 20.1K+ employees. |
| Who is the CEO of Charles River? | Charles River's CEO is Mr. James C. Foster. |
| Is Charles River publicy listed? | Yes, Charles River is a public company listed on NYS. |
| What is the stock symbol of Charles River? | Charles River trades under CRL ticker. |
| When did Charles River go public? | Charles River went public in 2000. |
| Who are competitors of Charles River? | Similar companies to Charles River include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Charles River? | Charles River's current market cap is $7.6B |
| What is the current revenue of Charles River? | Charles River's last 12 months revenue is $4.0B. |
| What is the current revenue growth of Charles River? | Charles River revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Charles River? | Current revenue multiple of Charles River is 2.6x. |
| Is Charles River profitable? | Yes, Charles River is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Charles River? | Charles River's last 12 months EBITDA is $963M. |
| What is Charles River's EBITDA margin? | Charles River's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Charles River? | Current EBITDA multiple of Charles River is 10.8x. |
| What is the current FCF of Charles River? | Charles River's last 12 months FCF is $483M. |
| What is Charles River's FCF margin? | Charles River's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Charles River? | Current FCF multiple of Charles River is 21.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
